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ABSTRACT
Background: In preclinical studies, bitter compounds, including quinine, stimulate secretion of glucoregulatory
hormones [e.g., glucagon-like peptide-1 (GLP-1)] and slow gastric emptying, both key determinants of postprandial
glycemia. A greater density of bitter-taste receptors has been reported in the duodenum than the stomach. Thus,
intraduodenal (ID) delivery may be more effective in stimulating GI functions to lower postprandial glucose.
Objective: We compared effects of intragastric (IG) and ID quinine [as quinine hydrochloride (QHCl)] administration on
the plasma glucose response to a mixed-nutrient drink and relations with gastric emptying, plasma C-peptide (reflecting
insulin secretion), and GLP-1.
Methods: Fourteen healthy men [mean ± SD age: 25 ± 3 y; BMI (in kg/m2): 22.5 ± 0.5] received, on 4 separate
occasions, in double-blind, randomly assigned order, 600 mg QHCl or control, IG or ID, 60 min (IG conditions) or 30 min
(IG conditions) before a mixed-nutrient drink. Plasma glucose (primary outcome) and hormones were measured before,
and for 2 h following, the drink. Gastric emptying of the drink was measured using a 13C-acetate breath test. Data were
analyzed using repeated-measures 2-way ANOVAs (factors: treatment and route of administration) to evaluate effects
of QHCl alone and 3-way ANOVAs (factors: treatment, route-of-administration, and time) for responses to the drink.
Results: After QHCl alone, there were effects of treatment, but not route of administration, on C-peptide, GLP-1, and
glucose (P < 0.05); QHCl stimulated C-peptide and GLP-1 and lowered glucose concentrations (IG control: 4.5 ± 0.1;
IG-QHCl: 3.9 ± 0.1; ID-control: 4.6 ± 0.1; ID-QHCl: 4.2 ± 0.1 mmol/L) compared with control. Postdrink, there were
treatment × time interactions for glucose, C-peptide, and gastric emptying, and a treatment effect for GLP-1 (all P < 0.05),
but no route-of-administration effects. QHCl stimulated C-peptide and GLP-1, slowed gastric emptying, and reduced
glucose (IG control: 7.2 ± 0.3; IG-QHCl: 6.2 ± 0.3; ID-control: 7.2 ± 0.3; ID-QHCl: 6.4 ± 0.4 mmol/L) compared with
control.
Conclusions: In healthy men, IG and ID quinine administration similarly lowered plasma glucose, increased plasma
insulin and GLP-1, and slowed gastric emptying. These findings have potential implications for lowering blood glucose
in type 2 diabetes. This study was registered as a clinical trial with the Australian New Zealand Clinical Trials at
www.anzctr.org.au as ACTRN12619001269123. J Nutr 2021;151:1453–1461.
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Introduction
Meal ingestion modulates a number of gastrointestinal (GI)
functions, including the secretion of glucoregulatory hormones
and gastric emptying, which are major determinants of
postprandial blood glucose concentrations (1, 2). Ingestion, or
intragastric or intraduodenal administration, of nutrients, e.g.,
protein, fatty acids or amino acids, as a ‘preload’ before a
meal, potently stimulates these functions (3–6). Glucagon-like
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peptide-1 (GLP-1) is of particular interest, given that it has been
shown to be a physiological modulator of postprandial glycemia
by glucose-dependent stimulation of insulin and suppression of
glucagon (7) and slowing of gastric emptying (8–10). Moreover,
GLP-1 agonists and dipeptidyl peptidase 4 inhibitors (which
increase endogenous GLP-1) are now used extensively in the
management of type 2 diabetes (11, 12). Gastric emptying plays
a key role in the postprandial glycemic response by regulating
the delivery, and subsequent absorption, of nutrients in the small
intestine, as well as the release of glucoregulatory hormones,
including GLP-1 (13).
There has been an increased interest in the therapeutic
potential of bitter compounds, subsequent to preclinical ob-
servations that they modulate both glucoregulatory hormones
and gastric emptying, by stimulating bitter-taste receptors
(TAS2Rs), present throughout the GI tract (14–21). For
example, berberine, denatonium benzoate, and phenylthiourea
stimulate the release of GLP-1 from the human enteroendocrine
cell lines NCI-H716 and HuTu-80 (18–20). Furthermore,
both an extract of bitter gourd and denatonium benzoate,
administered intragastrically, stimulate GLP-1 secretion and
reduce blood glucose in mice (19, 21). Furthermore, denatonium
benzoate increases contractility in both fundic and antral muscle
strips from mice, chloroquine and phenylthiocarbamide modu-
late smooth muscle contractility, and intragastric denatonium
benzoate and phenylthiocarbamide slow gastric emptying in
mice, via TAS2Rs (15). Denatonium benzoate also increased
plasma insulin and reduced plasma glucose, following glucose
gavage (5 g/kg) (19), and the glucose-lowering effect of wild
bitter gourd was abolished by pretreatment with the GLP-
1 antagonist exendin(9-39)amide, suggesting a key role for
GLP-1 (22).
There is only limited, as well as inconsistent, information
about the effects of bitter compounds in humans. Intragastric
administration of 100 mg bitter secoiridoids, an extract from
the root of Gentiana lutea, was reported to have a small,
albeit statistically nonsignificant, effect to stimulate GLP-1 (23).
Intraduodenal infusion of quinine, at doses of 37.5–225 mg,
over a 60-min period, had no effects on either plasma GLP-
1 or antropyloroduodenal pressures (3, 24), however, the low
infusion rate (2 mL/min) may have been insufficient to reach
a critical threshold for activation of TAS2Rs. In support of
this concept, in our recent study, intragastric administration
of 275 or 600 mg quinine enhanced the plasma insulin and
GLP-1 response to a mixed-nutrient drink consumed 30 min
later, associated with a reduction in plasma glucose, but no
effect on gastric emptying (25). While the latter observation
was consistent with the outcome of a study using a much
lower dose of quinine (18 mg) (26), it is also possible that
the time interval of 30 min between quinine administration
and drink consumption may have been insufficient for quinine
to reach intestinal TAS2Rs at a sufficient concentration to
induce feedback slowing of gastric emptying. This is supported
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by evidence from studies in mice to indicate a variable
regional distribution of TAS2Rs subtypes along the GI tract,
with a greater density of receptors in the duodenum than
the stomach (14). Accordingly, delivery of quinine to the
duodenum, and/or varying the timings of delivery between the
stomach and duodenum, may potentially affect the release of
glucoregulatory hormones, gastric emptying, and postprandial
glycemia differently.
The aim of the current study was to evaluate the comparative
effects of intragastric and intraduodenal administration of
quinine on the plasma glucose, C-peptide, and GLP-1 responses




Fourteen healthy male participants (mean age: 25 ± 2 y; BMI:
22.5 ± 0.5) participated in the study (Figure 1). The number of
participants was determined using power calculations based on our
previous work (25). We calculated that n = 14 participants would
allow the detection of a 0.8 mmol/L difference in peak plasma
glucose, which usually occurs approximately 30 min after ingestion
of a mixed-nutrient drink, with an SD of 1.1 mmol/L, at α = 0.05
and a power of 80%. Participants were recruited through flyers
placed around local universities and the Royal Adelaide Hospital and
advertisements in local newspapers. Participants were screened before
their inclusion to exclude those with GI symptoms or a history of
GI disease or surgery, vegetarians, smokers, an alcohol consumption
of >20 g/d on >5 d/wk, use of medications known to affect appetite,
energy intake, or GI function; high-performance athletes; unstable body
weight (≥5% change over the last 3 mo before participation) and
restrained eaters (score >12 on the restrained eating component of the
3-factor eating questionnaire) (27). The study protocol was approved by
the Human Research Ethics Committee of the Central Adelaide Local
Health Network and performed in accordance with the Declaration
of Helsinki. All participants provided written informed consent before
their inclusion. Once participants were enrolled, they were assigned
to 1 of 14 treatment orders (i.e., n = 1 randomly assigned to each
combination), using balanced random assignment generated with an
online tool (www.randomization.com), by a research officer who was
not involved in data analysis. Participants were compensated for the
time they spent involved in the study at a rate of AU$18/h, as approved
by the Ethics Committee.
Study outline
In a pilot study in 8 healthy male participants (mean age: 25 ± 3 y;
BMI: 21.9 ± 0.6 kg/m2), we determined the temporal profiles of
the plasma insulin and pyloric pressure (as a key determinant for
the slowing of gastric emptying) responses to intragastric (IG) and
intraduodenal (ID) bolus administration of 600 mg quinine hydrochlo-
ride (QHCl), dissolved in 10 mL distilled water (IG-QHCl and ID-
QHCl, respectively). Plasma insulin concentrations (means ± SEMs)
peaked ∼66 ± 7 min after IG-QHCl, and ∼33 ± 4 min after ID-
QHCl, while the peak number of pyloric pressure waves occurred
∼59 ± 17 min after IG-QHCl, and ∼29 ± 4 min after ID-QHCl. Thus,
IG-QHCl and ID-QHCl appeared to have maximum effects on plasma
insulin and pyloric pressures at ∼60 min and 30 min, respectively,
after administration. We therefore evaluated the effects of 600 mg IG-
QHCl or ID-QHCl, or IG-control or ID-control, administered 60 min
(IG conditions) or 30 min (ID conditions) before a mixed-nutrient
drink (Figure 2). The effect of quinine on plasma glucose was the
primary outcome, and effects on gastric emptying, and plasma GLP-
1 and C-peptide, were secondary outcomes. The 600-mg dose of QHCl
was selected as it lowered postprandial blood glucose in our previous
study (25).
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FIGURE 1 CONSORT flow diagram.
Preparation of treatments
The QHCl treatment was prepared by dissolving 600 mg QHCl
(Sinkona Indonesia Lestari) in 10 mL distilled water. The con-
trol treatment consisted of 10 mL distilled water. The treatments
were prepared on the morning of each study day, and filled in
syringes, by a research officer who had no involvement in data
analysis, and administered at a temperature of ∼30◦C. QHCl
and control treatments were indistinguishable, so that both the
study participants and the investigators performing the study were
blinded.
FIGURE 2 Schematic representation of the study design. (A) Study protocol for IG administration. At t = −61 min, after completion of phase
III and during phase I of fasting motor activity, a baseline blood sample and VAS ratings were collected, then either QHCl or control was
administered intragastrically within 1 min. 60 min later, at t = −1 min, each participant consumed, within 1 min, 350 mL of a mixed-nutrient
drink, containing 100 mg of 13C-acetate for measurement of gastric emptying by 13CO2 breath test. Blood samples, VAS ratings, and breath
samples were collected at the indicated time points throughout the study. (B) Study protocol for ID administration. On ID study days, the protocol
was identical to that on IG days, except the mixed-nutrient drink was consumed 30 min after administration of QHCl or control, which occurred
at t = −31 min, and blood sampling was adjusted accordingly. ID, intraduodenal; IG, intragastric; QHCl, quinine hydrochloride; VAS, visual analog
scale.
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Study protocol
Participants were studied on 4 occasions, each separated by 3–7 d in
a randomized, double-blind fashion. Participants were instructed to
refrain from vigorous physical activity and alcohol consumption for
24 h prior to each study and provided with a standardized meal (beef
lasagne; total energy content: 602 kcal; McCain Food) to be consumed
by 19:00 the night prior to each study visit. The following morning,
participants attended the Clinical Research Facility at the Adelaide
Medical School, University of Adelaide, at 08:15 after an overnight fast
(from both solids and fluids except water after 19:00, and from water
after 06:30).
Upon arrival, participants were intubated with a manometric
catheter (Dentsleeve International, Mui Scientific; total length: 100 cm;
external diameter: 3.5 mm), which was inserted through an anesthetized
nostril into the stomach and positioned across the pylorus as described
previously (4, 5, 28). The most proximal antral channel was used for IG
administration, and an additional infusion channel, located ∼14.5 cm
distal to the pylorus, for ID administration. Once the catheter was in
position [within ∼49 ± 8 min (mean ± SEM) across study days and
participants], an intravenous cannula was placed into a forearm vein
and the arm wrapped in a heat pad for regular sampling of arterialized
blood. Immediately following the completion of phase III of the fasting
migrating motor complex (i.e., during phase I, a period of motor
quiescence), data from a baseline blood sample and visual analog scale
(VAS) questionnaire to assess GI symptoms were collected. After fasting
motility was monitored for 10 min, QHCl or control was administered
into either the stomach (t = −61 min) or duodenum (t = −31 min), and
the catheter was then removed. At t = −1 min, participants consumed,
within 1 min, a 350-mL mixed-nutrient drink (Resource plus; Nestle,
325 mL: 500 kcal, 74 g carbohydrates, including maltodextrin and
sucrose, 18 g protein, and 15 g fat, plus 25 mL water to make up the final
volume), which included 100 mg 13C-acetate for measurement of gastric
emptying by breath test (29). Blood samples for measurement of plasma
glucose, C-peptide, and GLP-1 concentrations, VAS ratings, and breath
samples were collected at regular time intervals. At t = 120 min, the
intravenous cannula was removed, and each participant was provided
with a light lunch, after which they were allowed to leave the laboratory.
On a separate day, oral taste detection thresholds for QHCl were
quantified to ensure that all participants detected QHCl (25).
Measurements
Oral quinine taste thresholds.
Oral detection thresholds for QHCl were quantified using the
ascending-series 3-alternative forced-choice technique (30) and concen-
trations described in detail elsewhere (25).
Plasma glucose and hormone analyses.
Blood samples were collected into ice-chilled ethylenediaminetetraacetic
acid tubes and centrifuged at ∼1832 × g for 1 min at 4◦C within 15 min
of collection, before being stored at −80◦C until subsequent analysis.
Plasma glucose concentrations (mmol/L) were measured by the
glucose oxidase method, using a glucose analyzer (YSI 2300 Stat
Plus, Yellow Springs Instruments). Plasma C-peptide concentrations
(pmol/L), a measure of insulin secretion (31), were quantified using an
ELISA immunoassay (10-1136-01, Mercodia) (32). Plasma total GLP-
1 concentrations (pmol/L) were quantified using a radioimmunoassay
(GLPIT-36HK, Millipore) (25).
Gastric emptying.
13CO2 concentrations in end-expiratory breath samples were measured
using an isotope ratio mass spectrometer (FANCi; Fischer Analysen
Instrumente GmbH). The results were expressed as percentage of 13CO2
recovery/h and profiles plotted as cumulative values over the sampling
period (29).
GI symptoms.
Nausea and bloating were evaluated using a 100-mm VAS questionnaire
(33). Participants rated how they were feeling at a given time point by
placing a vertical stroke at the appropriate point on each line.
Data and statistical analysis
Statistical analysis was performed using SPSS software (version 26.0;
IBM). Plasma glucose, C-peptide, and GLP-1 concentrations and gastric
emptying data were expressed as absolute values, while VAS scores were
expressed as changes from baseline.
Effects of QHCl alone (i.e., prior to ingestion of the mixed-
nutrient drink) on plasma glucose, C-peptide, and GLP-1 concentrations
and VAS ratings were evaluated by calculating mean values, i.e.,
mean −61to −1 min and mean −31 to −1 min, so the 2 baseline periods
could be compared, despite different durations. These means, as
well as the effects at t = −1 min, were analyzed using repeated-
measures 2-way ANOVAs with treatment (QHCl, control) and route of
administration (IG, ID) as factors. To evaluate responses to the mixed-
nutrient drink, plasma glucose, C-peptide, GLP-1, and gastric emptying
were analyzed using repeated-measures 3-way ANOVAs with treatment
(QHCl, control), route of administration (IG, ID), and time (t = 0–
120 min for plasma glucose, C-peptide, GLP-1 at 7 levels, i.e., t = 10,
20, 30, 45, 60, 90, 120 min; for gastric emptying at 17 levels, i.e., t = 0,
5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 105, and 120 min) as
factors. Peak plasma glucose, and time to peak concentrations, as well as
VAS ratings, expressed as AUCs (AUC−1 to 120 min), were analyzed using
repeated-measures 2-way ANOVAs with treatment (QHCl, control) and
route of administration (IG, ID) as factors. Post hoc comparisons, with
P values adjusted for multiple comparisons by Bonferroni’s correction,
were performed where ANOVAs revealed significant main effects or
interaction. Sphericity of the time effect was evaluated by Mauchly’s
test and, when violated, the adjusted Greenhouse–Geisser P value was
reported. Normality and variance assumptions of ANOVA analyses
were assessed via residual plots and were acceptable for all models.
Correlations between plasma glucose at t = −1 to 30 min (expressed
as AUC−1 to 30 min), reflecting the early glucose response, with gastric
emptying between t = 0–30 (AUC0–30 min) and C-peptide and GLP-1,
both at t = −1 min and between t = −1 to 30 min (AUC−1 to 30 min),
were evaluated, using data across all study days, with the use of linear
within-subject correlations (34). All data are reported as means ± SEMs.
All tests were 2-tailed, and differences were considered statistically
significant at P ≤ 0.05.
Results
All participants tolerated the study treatments well and
completed all study visits without reporting any adverse effects.
QHCl was detected orally in all participants, with a mean
detection threshold of 0.15 ± 0.06 mmol/L. Breath test data
were unavailable in 2 participants due to technical problems.
Plasma glucose concentrations
There were no differences in baseline concentrations of plasma
glucose between study days. (Figure 3A).
Response to QHCl alone.
There were effects of treatment, but not of route of administra-
tion, on mean plasma glucose concentration (P < 0.001) and
plasma glucose at t = −1 min (P = 0.017); QHCl reduced
mean plasma glucose (P = 0.017) and plasma glucose at t =
−1 min (P < 0.001), albeit modestly, compared with control
(Figure 3A, Table 1).
Response to the drink.
Plasma glucose increased on all study days. There was a
treatment × time interaction (P = 0.001), but no effect of route
of administration, on plasma glucose concentrations; QHCl
reduced plasma glucose between t = 10–45 min, compared
with control (all P < 0.0.24) (Figure 3A). There were effects
of treatment, but not of route of administration, on both peak
plasma glucose (P = 0.001) and the time to peak glucose
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FIGURE 3 Plasma glucose (A), C-peptide (B), and GLP-1 (C)
concentrations after IG QHCl or control (t = −61 to −1 min), or ID
QHCl or control (t = −31 to −1 min), and after a mixed-nutrient
drink (t = 0–120 min) in healthy men. To evaluate effects of QHCl
alone, data were analyzed using repeated-measures 2-way ANOVAs
(factors: treatment, route of administration), to evaluate responses
to the drink, we used repeated-measures 3-way ANOVAs (factors:
treatment, route of administration, time). (A) Response to QHCl alone:
QHCl and control differ at that time, ∗P < 0.001. Response to the drink:
QHCl and control differ at that time, all #P < 0.024. (B) Response
to QHCl alone: QHCl and control differ at that time, ∗P = 0.002.
Response to the drink: QHCl and control differ at that time, both
#P < 0.008, and trend for QHCl and control to differ at that time,
$P = 0.052. (C) Response to QHCl alone: QHCl and control differ at
that time, ∗P = 0.002. Response to the drink: QHCl and control differ,
#P = 0.003. Blood samples were not analyzed for GLP-1 at t = −51,
−41, −31 and 90 min on IG study days and at t = 90 min on ID study
days. Data are means ± SEMs; n = 14. GLP-1, glucagon-like peptide-
1; ID, intraduodenal; IG, intragastric; QHCl, quinine hydrochloride.
(P = 0.006); QHCl lowered peak glucose, (P = 0.006) and
increased the time to peak glucose (P = 0.001), compared with
control (Table 1).
Plasma C-peptide concentrations
There were no differences in baseline C-peptide concentrations
between study days (Figure 3B).
Response to QHCl alone.
There were effects of treatment, but not of route of adminis-
tration, on mean plasma C-peptide concentration (P = 0.002)
and concentrations at t = −1 min (P = 0.001); QHCl increased
mean C-peptide (P = 0.002) and concentration at t = −1 min
(P = 0.001), albeit modestly, compared with control (P < 0.05)
(Figure 3B, Table 1).
Response to the drink.
Plasma C-peptide increased markedly on all study days. There
was a treatment × time interaction (P = 0.011), but no effect of
route of administration, on plasma C-peptide; QHCl increased
C-peptide at t = 10 and 120 min (both P < 0.008), and tended
to stimulate C-peptide at t = 90 min (P = 0.052), compared
with control (Figure 3B).
Plasma GLP-1 concentrations
There were no differences in baseline GLP-1 concentrations
between study days (Figure 3C).
Response to QHCl alone.
There were effects of treatment, but not of route of admin-
istration, on mean plasma GLP-1 concentration (P = 0.002)
and concentrations at t = −1 min (P = 0.011); QHCl
increased mean plasma GLP-1 concentration (P = 0.002) and
concentrations at t = −1 min (P = 0.011), albeit modestly,
compared with control (Figure 3C, Table 1).
Response to the drink.
Plasma GLP-1 increased markedly on all study days. There
was an effect of treatment (P = 0.003), but not of route
of administration, on plasma GLP-1; QHCl increased plasma
GLP-1 compared with control (P = 0.003) (Figure 3C).
Gastric emptying
There was a treatment × time interaction, but no effect of route
of administration, on gastric emptying of the drink (P = 0.003);
QHCl slowed gastric emptying modestly between t = 20–
75 min, compared with control (all P < 0.016) (Figure 4).
Relations between plasma glucose with gastric
emptying, C-peptide, or GLP-1
There was a direct correlation between early plasma glu-
cose AUC−1 to 30 min and early gastric emptying AUC0–30 min
(r = 0.621, P < 0.001), and an inverse correlation with C-
peptide at t = −1 min (r = −0.265, P = 0.048). There were no
correlations between early plasma glucose AUC−1 to 30 min and
early C-peptide AUC−1 to 30 min, GLP-1 AUC−1 to 30 min or GLP-1
at t = −1 min.
GI symptoms
There were no effects of treatment or route of administration on
ratings of nausea or bloating, either in response to QHCl alone,
or the mixed-nutrient drink (Figure 5).







niversity of Adelaide user on 01 Septem
ber 2021
TABLE 1 Mean concentrations and concentrations at t = −1 min, of plasma glucose and
hormones following IG or ID administration of 600 mg QHCl or control, and peak and time to peak of












Mean conc, mmol/L3 4.5 ± 0.1 4.4 ± 0.1 4.6 ± 0.1 4.4 ± 0.2 <0.001∗
t = −1 min, mmol/L 4.5 ± 0.1 3.9 ± 0.1 4.6 ± 0.1 4.2 ± 0.1 0.017∗
Postdrink peak glucose, mmol/L 7.2 ± 0.3 6.2 ± 0.3 7.2 ± 0.3 6.4 ± 0.4 0.001∗
Postdrink time to peak glucose, min 43 ± 5 58 ± 8 45 ± 7 69 ± 9 0.006∗
Plasma C-peptide
Mean conc, pmol/L3 231 ± 41 394 ± 51 321 ± 60 446 ± 76 0.002∗
t = −1 min, pmol/L 312 ± 53 687 ± 126 278 ± 76 589 ± 75 0.001∗
Plasma GLP-1
Mean conc, pmol/L3 19.2 ± 1.2 22.5 ± 1.9 19.9 ± 1.4 22.3 ± 1.6 0.002∗
t = −1 min, pmol/L 19.4 ± 1.2 22.1 ± 2.1 19.0 ± 1.5 26.0 ± 2.5 0.011∗
1Data are means ± SEMs unless otherwise indicated, n = 14. Data were analyzed using repeated-measures 2-way ANOVA with
treatment and route of administration as factors. ∗Qunine significantly different from control. ID, intraduodenal; IG, intragastric;
QHCl, quinine hydrochloride.
2Only significant main effects or interactions are shown.
3Mean concentration calculated for t = −61 to −1 min for IG conditions, and for t = −31 to −1 min for ID conditions.
Discussion
Our study compared the effects of IG and ID administration
of quinine on the plasma glucose response to a mixed-nutrient
drink, and relations with plasma C-peptide and GLP-1 levels
and gastric emptying, in healthy men. Our key findings were
that quinine lowered plasma glucose and stimulated plasma C-
peptide and GLP-1, both alone and following the drink, and
slowed gastric emptying of the drink, without any difference
between the IG and ID routes of administration. These
observations have important implications for the potential
clinical use of bitter compounds to lower postprandial blood
glucose.
FIGURE 4 Gastric emptying of a mixed-nutrient drink, measured
by 13C-acetate breath test, 60 min after IG, or 30 min after ID,
administration of either QHCl (IG-QHCl or ID-QHCl, respectively)
or control (IG-control or ID-control, respectively) in healthy men.
Data were analyzed using repeated-measures 3-way ANOVA, with
treatment, route of administration and time as factors. # QHCl and
control differ at that time, all P < 0.016. Data are means ± SEMs;
n = 12. ID, intraduodenal; IG, intragastric; QHCl, quinine hydrochloride.
That quinine lowers plasma glucose confirms our recent
findings that 600 mg quinine, administered intragastrically,
reduced the plasma glucose response to a mixed-nutrient drink
consumed 30 min after quinine (25). In the current study we
hypothesized that additional time would be required following
IG administration for quinine to reach a sufficient number
of bitter receptors, when compared with ID administration,
because a greater number of bitter receptors has been reported
in the duodenum, compared with the stomach (14). Accordingly,
IG quinine was administered 60 min, and ID quinine 30 min,
prior to the drink. The plasma glucose–lowering effect of
quinine was comparable and substantial in both conditions.
Thus, the time difference of 30 min between IG and ID
quinine administration appears sufficient for IG quinine to
empty into the duodenum to activate small intestinal bitter
receptors or, alternatively, to activate a greater number of gastric
bitter receptors. This result is promising, as administration
into the stomach can be easily achieved using encapsulation
technologies, which would also conceal the aversive taste of
bitter compounds in a practical setting.
To our knowledge, this is only the second study that has
evaluated the effects of a bitter compound, administered into
the GI lumen, on insulin secretion (as measured by C-peptide) in
humans. In our recent study in healthy men, IG administration
of quinine, at doses of 275 or 600 mg, modestly stimulated
insulin immediately before a mixed-nutrient drink, consumed
30 min later, and the insulin response to the nutrient drink
was also enhanced (within 15 min), associated with a lowering
of plasma glucose within 30 min (25). Because the quinine-
induced stimulation of insulin before the drink was small, but
rising, we hypothesized that the interval of 30 min between
IG quinine administration and drink consumption may have
been insufficient for more substantive insulin stimulation. In
the current study, quinine, in a dose of 600 mg, modestly
stimulated C-peptide, within 30 min of ID, and 60 min of
IG, administration, with no difference between the routes of
administration, associated with lowering of fasting glucose. C-
peptide increased much more after the drink, and this rise was
greater following both IG and ID quinine. An increase in insulin
is likely to be primarily responsible for the reduction in plasma
glucose. Indeed, we found an inverse relation between the early
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FIGURE 5 Scores for nausea (A) and bloating (B) in response to
IG QHCl or control (t = −61 to −1 min; IG-QHCl or IG-control,
respectively), or ID QHCl or control (t = −31 to −1 min; ID-QHCl or ID-
control, respectively), and after a mixed-nutrient drink (t = 0–120 min)
in healthy men. Data are expressed as means ± SEMs; n = 14. ID,
intraduodenal; IG, intragastric; QHCl, quinine hydrochloride.
rise in plasma glucose postdrink and the rise in C-peptide
immediately before the drink. The mechanism(s) underlying the
effect of quinine to stimulate insulin secretion are speculative.
The absorption of quinine into the bloodstream may stimulate
insulin by directly activating receptors on pancreatic beta cells.
This is likely, as intravenous quinine, when used to treat
malaria patients, markedly increases insulin, associated, not
infrequently, with hypoglycemia (35, 36). Moreover, while it
is unclear whether TAS2Rs are present on human pancreatic
beta cells, quinine induces insulin secretion from isolated murine
pancreatic beta cells in vitro (37). While we did not measure
glucagon in the current study, we have shown previously that
quinine stimulates glucagon secretion modestly (25); thus, it
is possible that glucagon may have somewhat attenuated the
glucose-lowering effect of quinine.
A number of bitter compounds, including berberine, 1,10-
phenanthroline, and denatonium benzoate, have been reported
to stimulate GLP-1 release from enteroendocrine cells (18,
20, 38). In our previous study (25), plasma GLP-1 increased
modestly in response to IG quinine at the doses of 275 and
600 mg. In the current study, both ID and IG administration of
600 mg quinine modestly stimulated GLP-1, with no difference
between the 2 routes at t = −1 min. This suggests that IG
administration requires a longer time for an effect comparable
to ID administration and, therefore, that exposure of small
intestinal bitter receptors to quinine is most likely required for
stimulation of GLP-1 release. The role of GLP-1 in the observed
glucose-lowering by quinine is unclear. While some studies
have shown that the insulinotropic effect of GLP-1 requires
circulating glucose concentrations of ∼7–8 mmol/L (33, 39),
other studies have reported that glucose concentrations of ∼4–
5 mmol/L are sufficient (40). In the current study, plasma glucose
reached ∼6–7 mmol/L, thus, the contribution of GLP-1 to the
stimulation of insulin was probably modest, and the magnitude
of this effect would need to be established with the use of a
GLP-1 receptor antagonist.
Gastric emptying is a key determinant of postprandial
blood glucose regulation. In contrast to our previous study, in
which quinine was administered intragastrically 30 min before
a mixed-nutrient drink, in the current study, administration
of the same dose of quinine, either intragastrically 60 min,
or intraduodenally 30 min, before the drink, slowed gastric
emptying. The underlying mechanisms are unknown, but may
potentially involve the release of gut hormones, including
CCKand GLP-1. Both have potent effects to slow gastric
emptying in humans (1, 41, 42). Since GLP-1 was increased
by quinine immediately before consumption of the nutrient
drink, it is possible that GLP-1 contributed to slowing of
gastric emptying, while the effect of quinine on CCK release
remains to be established. The slowing of gastric emptying
most likely contributed to postprandial blood glucose-lowering,
which was apparent for the first postprandial hour. Indeed, we
found a correlation between the early lowering of postprandial
glucose and slowing of gastric emptying. In contrast, in our
previous study (25), in which quinine stimulated insulin, but did
not slow gastric emptying, glucose-lowering occurred only at
around 30 min postmeal. Thus, when quinine administration is
carefully targeted, a potent and more prolonged effect to lower
postprandial blood glucose can be achieved by activating both
the secretion of insulin and slowing of gastric emptying. It is
also important to note that slowing of gastric emptying was not
due to an aversive effect of quinine, since participants did not
report any nausea. Studies in patients with type 2 diabetes are
now warranted to evaluate potential clinical benefits.
It is appropriate to recognize some limitations of our study.
We did not measure circulating quinine concentrations. We only
included male participants to avoid any confounding effect of
the menstrual cycle on gastric emptying (43), however, female
participants have been reported to have lower oral detection
thresholds for denatonium benzoate (44), suggesting that they
may also be more sensitive to intraluminal bitter stimuli. We did
not measure plasma ghrelin or motilin concentrations, which
are modulated by bitter substances (45, 46). However, since
both hormones, when administered exogenously, accelerate
gastric emptying (47, 48), and at least ghrelin is suppressed in
the postprandial state (1), they are unlikely to be involved in the
observed slowing of gastric emptying by quinine. Our study was
designed to evaluate the glycemic and gastric emptying effects
of quinine, using a standardized drink. Thus, the evaluation
of energy intake, which requires an ad libitum meal, was not
possible, and we did not measure appetite perceptions. Finally,
we cannot exclude the possibility that the effects of quinine
observed in our study, or previous studies using similarly high
doses, might be due to effects that did not involve activation of
bitter-receptors on enteroendocrine cells, e.g., direct effects of
circulating quinine on smooth muscle or pancreatic beta cells.
However, this was a “proof-of-principle” study, and given the
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potent effects that we observed, future studies will be able to
use lower doses. Moreover, the use of specific bitter-receptor
antagonists would assist in answering this question; however,
these antagonists are currently not available for use in humans.
In conclusion, our study established that quinine, when
allowed to sufficiently interact with small intestinal bitter re-
ceptors, reduces postprandial blood glucose by stimulating glu-
coregulatory functions, including C-peptide secretion and slow-
ing of gastric emptying, while the role of GLP-1 is somewhat
uncertain. Nevertheless, this study demonstrates potent blood
glucose–lowering effects of quinine in healthy people with good
glycemic control, thus warranting further research to investigate
the suitability of this bitter compound to improve postprandial
blood glucose in people with type 2 diabetes or impaired glucose
tolerance.
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